You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
<strong>IMS</strong> COM PANY PRO FILES NOVARTIS<br />
This ta ble shows the break down of the com pany’s phar ma ceu ti cal sales in terms of lead ing coun tries and<br />
sub sid iar ies. Sta tis tics for coun try share of cor po rate rev e nue, sub sid iary share of coun try rev e nue, US<br />
dol lar and US dol lar fixed rate growth over the pre vi ous twelve month pe riod are pre sented. Sales data<br />
cov ers the pe riod for the twelve months to September 2008.<br />
All of the sub sid iar ies men tioned above are 100%-owned by Novartis ex cept Novartis/P.Fabre, Ger many<br />
(50%-owned by Pi erre Fabre, France). Sales for a sub sid iary are al lo cated to the cor po ra tion with the ma -<br />
jor ity shareholding. In re la tion ships where there is a 50:50 shareholding, how ever, sales will con tinue to<br />
be split 50:50 be tween the two owning corporations.<br />
Pharmaceuticals: Top Five Third Level Therapeutic Classes<br />
ATC Therapeutic<br />
Class<br />
Description<br />
US<br />
Dollar<br />
Sales<br />
(‘000s)<br />
Share of<br />
Worldwide<br />
Corporate Sales<br />
%<br />
Percentage<br />
Growth Sep<br />
07/Sep 08<br />
USD USD FIXED<br />
RATE<br />
TOTAL SALES 36296737 100.0 8 1<br />
1 C9C ANGIOTEN-II ANTAG, PLAIN 3616125 10.0 19 12<br />
2 L1X ALL OTH. ANTINEOPLASTICS 3149187 8.7 23 14<br />
3 C9D ANGIOTEN-II ANTAG, COMB 2815218 7.8 34 28<br />
4 M5B BONE CALCIUM REGULATORS 1515000 4.2 19 13<br />
5 L4A IMMUNOSUPPRESSIVE<br />
AGENTS 1240800 3.4 14 5<br />
This ta ble shows the com pany’s top five third level ther a peu tic classes. Sales data cov ers the twelve<br />
month pe riod to Sep tem ber 2008. Sta tis tics for third-level ther a peu tic class share of cor po rate rev e nue,<br />
US dol lar and US dol lar fixed rate growth over the pre vi ous twelve month pe riod are presented.<br />
The lead ing five ther a peu tic classes ac count for 34.1% of cor po rate rev e nue.<br />
Pharmaceuticals: Leading International Products<br />
International<br />
Products<br />
Share of<br />
Worldwide<br />
Corporate Sales<br />
%<br />
Percentage<br />
Growth Sep<br />
07/Sep 08<br />
USD USD FIXED<br />
RATE<br />
TOTAL SALES 100.0 8 1<br />
1 DIOVAN 9.9 18 12<br />
2 GLIVEC 8.5 21 12<br />
3 CO-DIOVAN 6.8 20 14<br />
4 ZOMETA 3.9 19 14<br />
5 VOLTAREN 3.4 14 4<br />
6 FEMARA 2.8 28 21<br />
7 SANDOSTATIN 2.7 11 5<br />
8 SANDIMMUN 2.4 6 -3<br />
9 EXELON 2.1 31 22<br />
10 LUCENTIS 1.9 354 312<br />
© 2009 <strong>IMS</strong> Health In cor po rated or its af fil i ates Page 120
Change language